Green Lifescience Co., Ltd.

KOSDAQ:A114450 Stock Report

Market Cap: ₩35.4b

Green Lifescience Valuation

Is A114450 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A114450 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A114450's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A114450's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A114450?

Key metric: As A114450 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A114450. This is calculated by dividing A114450's market cap by their current revenue.
What is A114450's PS Ratio?
PS Ratio1.4x
Sales₩24.60b
Market Cap₩35.42b

Price to Sales Ratio vs Peers

How does A114450's PS Ratio compare to its peers?

The above table shows the PS ratio for A114450 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.9x
A225220 Genolution
3.9xn/a₩44.5b
A331920 Celemics
4.7xn/a₩28.6b
A036180 GW VitekLTD
1.4xn/a₩53.9b
A086040 Biotoxtech
1.5xn/a₩50.8b
A114450 Green Lifescience
1.4xn/a₩35.4b

Price-To-Sales vs Peers: A114450 is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (2.9x).

Price to Sales Ratio vs Industry

How does A114450's PS Ratio compare vs other companies in the KR Life Sciences Industry?

2 CompaniesPrice / SalesEstimated GrowthMarket Cap
A245620 Eone Diagnomics Genome Center
0.8xn/aUS$41.47m
A215380 WOOJUNG BIO
0.7xn/aUS$23.20m
No more companies available in this PS range
A114450 1.4xIndustry Avg. 3.8xNo. of Companies7PS048121620+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: A114450 is good value based on its Price-To-Sales Ratio (1.4x) compared to the KR Life Sciences industry average (3.8x).

Price to Sales Ratio vs Fair Ratio

What is A114450's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A114450 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.4x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A114450's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩273,500.00

7D

0.9%

1Y

75.3%

J2KBIO

₩52.9b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,260.00

7D

-5.8%

1Y

n/a

Medy-Tox

₩883.1b

Operates as a biopharmaceutical company in South Korea.

A086900

₩131,200.00

7D

1.7%

1Y

-39.0%